Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hepatitis B virus (HBV) preS protein refers to the preS1 and preS2 domains found in the large and middle surface proteins of HBV, which are critical for viral infectivity, host cell entry, immune recognition, and vaccine design. The preS1 domain contains the receptor-binding site essential for attachment to hepatocytes via interaction with NTCP. Both preS1 and preS2 contain immunogenic T-cell and B-cell epitopes, making them targets for vaccine development and diagnostic applications. Myrcludex B is an example of a drug that targets the preS1 domain to inhibit viral entry.
NTCP binding inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus preS protein (preS).